Medulloblastoma Survival Rate: Key Insights and Prognosis

About three in four children diagnosed with medulloblastoma survive at least five years, a figure that has improved substantially over the past few decades but still masks enormous variation depending on tumor biology, spread at diagnosis, and treatment received. A large analysis of the U.S. SEER cancer registry found five-year survival for children with medulloblastoma at roughly 75%, with ten-year survival around 68%.¹ That single number, though, can be misleading. A child whose tumor belongs to the WNT molecular subgroup has better than a 90% chance of being alive five years later; a child with a high-risk Group 3 tumor and certain genetic amplifications can face a five-year survival near zero. Understanding what drives those differences is the real insight behind medulloblastoma prognosis.

Molecular Subgroups Matter More Than Almost Anything Else

Medulloblastoma is not one disease. Researchers have identified four major molecular subgroups, each with distinct biology and sharply different outcomes. This classification has become the backbone of how doctors assess prognosis and plan treatment.

The WNT subgroup carries the best prognosis, with five-year overall survival exceeding 90%.² These tumors tend to have a specific mutation in the CTNNB1 gene and a characteristic loss of chromosome 6. Because outcomes are so favorable, clinical trials have explored whether treatment can be dialed back to reduce long-term side effects. Two early de-intensification trials that tried eliminating craniospinal radiation had to be stopped because relapse rates climbed too high, suggesting that radiation remains essential even in this lower-risk group.² A more recent trial took a gentler approach, reducing the dose of craniospinal radiation and chemotherapy rather than eliminating them entirely, and found that progression-free survival stayed above 90%.³ That is a meaningful advance: if you can give less radiation and less chemo and still cure the cancer, the child walks away with fewer lasting problems.

The SHH (Sonic Hedgehog) subgroup has an intermediate prognosis overall, with five-year survival in the range of 58–62% in a large cohort study, but the picture shifts dramatically depending on age and genetics.⁴ One critical modifier is whether the tumor carries a TP53 mutation. In children over five with SHH medulloblastoma, a TP53 mutation drops five-year survival to about 41%, compared with 81% for those without the mutation. TP53 mutations accounted for nearly three-quarters of deaths in that age bracket.⁵ An earlier study put it even more starkly: among average-risk patients, five-year survival for TP53-mutated tumors was 0%, versus about 74% for those without the mutation.⁶ In practical terms, TP53 status in an SHH tumor is one of the single most important pieces of information a family can receive.

Group 3 medulloblastoma is the most aggressive subgroup. It is frequently metastatic at diagnosis and historically has the worst outcomes.⁷ Researchers have further split Group 3 into risk tiers using gene expression markers and MYC amplification status. At the favorable end, patients without metastatic spread, without MYC amplification, and with low expression of a gene called KIRREL2 had a remarkable five-year survival of 95%. At the other extreme, all patients with MYC-amplified Group 3 tumors in that study had zero five-year survival.⁸ This kind of granularity is reshaping how oncologists think about Group 3: the label alone no longer tells you enough.

Group 4 is the most common subgroup and carries an intermediate prognosis. Recent molecular work has carved out a favorable-risk subset of Group 4 patients, defined by specific chromosomal features and absence of metastasis, whose five-year progression-free survival reached 97%. On the other end, patients with metastatic disease and unfavorable chromosomal profiles had a five-year progression-free survival of 49%.⁹ Like Group 3, a single subgroup label hides a wide survival spectrum.

Metastatic Spread and Residual Tumor After Surgery

Beyond molecular subgroup, two clinical factors have long anchored how risk is assessed: whether the tumor has spread (metastasized) at the time of diagnosis, and how much tumor remains after surgery.

Metastatic disease at diagnosis clearly worsens the outlook. A Children’s Cancer Group study found that five-year progression-free survival for children with no spread was about 70%, dropping to roughly 57% with limited spread and about 40% with more extensive spread.¹⁰ An international meta-analysis of young children confirmed that both incomplete resection and metastasis independently worsen event-free and overall survival.¹¹

The question of how aggressively to pursue a complete surgical removal turns out to be more nuanced than it once seemed. A systematic review found the evidence genuinely mixed: some studies linked greater extent of resection to better survival, others did not, and studies that accounted for molecular subgroup found no clear link between extent of resection and overall survival.¹² A multi-cohort analysis of over 1,100 patients found that when subtotal resection was the only risk factor present — no metastasis, no aggressive histology — survival was comparable to standard-risk disease.¹³ A separate subgroup-specific analysis found that the survival advantage of complete resection disappeared for WNT, SHH, and Group 3 tumors once molecular subgroup was taken into account. The one exception was Group 4 tumors with metastatic disease, where gross total resection did offer a progression-free survival benefit.¹⁴ The practical upshot: surgeons still aim for maximum safe removal, but pushing for a total resection at the cost of serious neurological damage may not be justified when the residual tumor is small.

Histology Still Plays a Role

Even with molecular subgrouping available, the tumor’s microscopic appearance provides independent prognostic information. The large cell/anaplastic (LCA) variant carries the worst prognosis among histological types. One study found five-year progression-free survival of about 44% for LCA tumors, compared with 78% for classic medulloblastoma and 82% for the desmoplastic variant.¹⁵ That gap held up in multivariate analysis, meaning LCA histology predicts worse outcomes even after accounting for other known risk factors. When LCA histology is combined with MYC gene amplification, the situation is especially grim: one study reported a four-year event-free survival of just 22% in children with both features.¹⁶

The desmoplastic nodular variant and a related pattern called MBEN (medulloblastoma with extensive nodularity) tend to have the most favorable histological prognosis, particularly in infants. These tumors frequently fall within the SHH molecular subgroup and are often treated with chemotherapy-heavy protocols that avoid or delay radiation in very young children.¹¹

Radiation, Proton Therapy, and Younger Children

Craniospinal irradiation — radiation delivered to the entire brain and spine — remains central to medulloblastoma treatment for most patients older than about three to five years. An important development in recent years is the growing use of proton beam therapy instead of traditional photon radiation. Proton beams can be shaped more precisely, potentially sparing healthy tissue behind the tumor. Two recent meta-analyses both found that proton and photon therapy produce similar survival rates.¹⁷ The real advantage of protons shows up in side effects: lower rates of thyroid problems, less neurocognitive decline (on the order of a 13-point IQ advantage), and fewer blood-related and eye-related complications.¹⁸ When the cure rate is the same but the long-term burden is lighter, that matters enormously for a child who may live another sixty or seventy years.

For infants and toddlers, radiation poses an especially severe threat to the developing brain. Treatment strategies for this group rely heavily on high-dose chemotherapy, sometimes followed by autologous stem cell rescue, to avoid or postpone radiation. This approach has shown favorable results particularly for SHH-type tumors in young children.¹⁹ Some protocols have incorporated intrathecal chemotherapy as a maintenance strategy to avoid whole-brain radiation while preserving cognitive function.²⁰

What Happens When Medulloblastoma Comes Back

Relapse is the event families dread most, and the statistics are sobering. For patients who have already received radiation and then relapse, treatment is often no longer curative. In a multi-institutional Korean study, five-year progression-free survival after recurrence in previously irradiated patients was only about 7%, and five-year overall survival was about 28%.²¹ Focal relapses fare better than diffuse ones, and adding chemotherapy to salvage treatment was associated with better survival in that cohort.

The molecular subgroup also shapes what relapse looks like. Group 3 tumors tend to relapse earlier than Group 4 tumors. Both groups commonly relapse at distant sites, but the pattern of distant disease matters: nodular relapses in Group 3 and Group 4 were associated with longer survival after relapse compared with diffuse spread.²² For most patients with relapsed medulloblastoma who have already been irradiated, the honest reality is that care shifts toward prolonging life and managing symptoms rather than aiming for cure.²³

Adults With Medulloblastoma

Medulloblastoma is often described as a childhood cancer, but roughly a quarter to a third of cases occur in adults. A striking finding from SEER data is that five-year survival in adults (about 79%) and children (about 75%) is similar when the analysis excludes a related tumor type called supratentorial primitive neuroectodermal tumor.²⁴ The challenge for adults is that far fewer prospective clinical trials have been designed specifically for them, so treatment decisions often rely on protocols developed for children.²⁵ Adult tumors also have a different distribution of molecular subgroups — SHH tumors are more common in adults than in children — which means treatment may eventually need to be tailored differently as subgroup-specific protocols mature.

Life After Treatment

Surviving medulloblastoma is not the same as returning to baseline health. The treatments that cure the tumor, particularly craniospinal radiation, leave lasting marks. Common long-term problems include hearing loss, endocrine deficiencies (thyroid dysfunction, growth hormone deficiency, delayed puberty), and neurocognitive impairment.²⁶ Cognitive scores tend to decline over time rather than stabilize, and studies have found signs of premature aging in long-term survivors, including elevated rates of diabetes, hypertension, and second cancers.²⁷ Working memory, in particular, continues to decline with time since diagnosis in a pattern that resembles normal aging but happens decades too early.

This is why reducing treatment intensity for favorable-risk groups is not just an academic exercise. Every fraction of radiation dose that can be safely spared, and every cycle of chemotherapy that can be dropped without compromising cure, translates directly into fewer years of hearing aids, fewer hormone injections, and better school and job performance for children who grow up to be adults.

Where You Get Treated Can Affect Your Outcome

Access to specialized care makes a measurable difference. A study using U.S. national cancer data found that being treated at a low-volume facility was independently associated with worse overall survival for young children with medulloblastoma, with a risk increase comparable to having metastatic disease.²⁸ Deferral of postoperative radiation was also linked to poorer survival in that analysis.

Socioeconomic factors compound the problem. A population-based study found that insurance status, income level, and place of residence all correlated with medulloblastoma outcomes, with the effects differing by sex. For women, lacking insurance was one of the strongest negative predictors of survival. For men, unemployment and unmarried status were associated with worse prognosis.²⁹ Hispanic ethnicity and non-private insurance were identified as risk factors for worse survival in pediatric medulloblastoma specifically.³⁰ None of these factors reflect tumor biology. They reflect gaps in access, timeliness of treatment, and the quality of supportive care available.

Liquid Biopsies and Earlier Detection of Relapse

One of the most promising developments in medulloblastoma monitoring is the use of liquid biopsies — specifically, analyzing tumor DNA that is shed into cerebrospinal fluid. Traditional surveillance relies on periodic MRI scans, which can only detect relapse once a visible mass has formed. Liquid biopsies aim to catch recurrence earlier, when tumor DNA starts appearing in the fluid even before anything shows up on imaging.

A prospective study of 123 children with medulloblastoma found that measurable residual disease in cerebrospinal fluid was detectable at diagnosis in 85% of patients with metastatic disease and 54% with localized disease. The number of patients with detectable tumor DNA declined during treatment, but those with persistent signal had a substantially higher risk of progression. Crucially, in half the patients who eventually relapsed after achieving a complete response on imaging, the liquid biopsy flagged disease at least three months before the MRI showed anything, with a median lead time of over eight months.³¹ Separate work has confirmed that higher levels of tumor DNA in cerebrospinal fluid correlate with more aggressive tumors and earlier progression.³² This technology is not yet part of standard care everywhere, but it has the potential to shift how relapse is detected and to open a window for earlier intervention.

Experimental Approaches on the Horizon

For patients whose tumors resist standard treatment — particularly high-risk Group 3 tumors, TP53-mutated SHH tumors, and relapsed disease — researchers are exploring targeted therapies and immunotherapy. The molecular profiling that now classifies medulloblastoma into subgroups has also revealed specific signaling pathways that could be druggable targets.³³

CAR T-cell therapy, which engineers a patient’s own immune cells to recognize and attack tumor cells, is being investigated for medulloblastoma. Early lab work has identified tumor markers like GPC2 that could serve as targets, and animal studies have shown tumor reduction with CAR T-cells delivered directly into the brain’s fluid compartments. The intracerebroventricular route — injecting therapy directly into the brain’s ventricles rather than into a vein — appears to improve potency while reducing systemic toxicity.³⁴ Drug repurposing efforts are also underway; venetoclax, an existing leukemia drug, has shown enough activity in medulloblastoma cell lines to warrant further preclinical study.³⁵ None of these approaches are ready for routine clinical use, but they represent the clearest path toward improving outcomes for the patients who currently fare worst.